These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693 [TBL] [Abstract][Full Text] [Related]
9. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900 [TBL] [Abstract][Full Text] [Related]
10. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Nair RR; Emmons MF; Cress AE; Argilagos RF; Lam K; Kerr WT; Wang HG; Dalton WS; Hazlehurst LA Mol Cancer Ther; 2009 Aug; 8(8):2441-51. PubMed ID: 19671765 [TBL] [Abstract][Full Text] [Related]
11. ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR). Xu X; Wang Q; He Y; Ding L; Zhong F; Ou Y; Shen Y; Liu H; He S Ann Hematol; 2017 May; 96(5):847-858. PubMed ID: 28238095 [TBL] [Abstract][Full Text] [Related]
12. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Bjorklund CC; Baladandayuthapani V; Lin HY; Jones RJ; Kuiatse I; Wang H; Yang J; Shah JJ; Thomas SK; Wang M; Weber DM; Orlowski RZ Leukemia; 2014 Feb; 28(2):373-83. PubMed ID: 23760401 [TBL] [Abstract][Full Text] [Related]
13. A role for activator of G-protein signaling 3 (AGS3) in multiple myeloma. Shao S; Huang X; Wang Y; He S; Xu X; Zhu X; Yang X; Ding Z; Yao L; Huang Y; Wang C Int J Hematol; 2014 Jan; 99(1):57-68. PubMed ID: 24307516 [TBL] [Abstract][Full Text] [Related]
14. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505 [TBL] [Abstract][Full Text] [Related]
15. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719 [TBL] [Abstract][Full Text] [Related]
17. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939 [TBL] [Abstract][Full Text] [Related]
18. Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM). Huang Y; Huang X; Cheng C; Xu X; Liu H; Yang X; Yao L; Ding Z; Tang J; He S; Wang Y BMC Cancer; 2019 Dec; 19(1):1269. PubMed ID: 31888545 [TBL] [Abstract][Full Text] [Related]
19. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Kobune M; Chiba H; Kato J; Kato K; Nakamura K; Kawano Y; Takada K; Takimoto R; Takayama T; Hamada H; Niitsu Y Mol Cancer Ther; 2007 Jun; 6(6):1774-84. PubMed ID: 17575106 [TBL] [Abstract][Full Text] [Related]
20. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Mori Y; Shimizu N; Dallas M; Niewolna M; Story B; Williams PJ; Mundy GR; Yoneda T Blood; 2004 Oct; 104(7):2149-54. PubMed ID: 15138161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]